Aton Pharma buys rights to Merck’s Timoptic

LAWRENCEVILLE, N.J. A large drug maker has sold the right to market one of its drugs in the United States to a smaller company.

Aton Pharma announced Wednesday that it had bought rights to Merck & Co.’s Timoptic (timolol maleate), a treatment for symptoms of ocular hypertension and open-angle glaucoma. Open-angle glaucoma affects as many as 2.25 million people in the United States.

Aton Pharma announced Wednesday that it had bought rights to Merck & Co.’s Timoptic (timolol maleate), a treatment for symptoms of ocular hypertension and open-angle glaucoma. Open-angle glaucoma affects as many as 2.25 million people in the United States.

Financial terms of the acquisition were not disclosed.